Clearmind Medicine Inc. (NASDAQ: CMND) announced the publication of a Japanese patent application for its proprietary compositions containing 5-Methoxy-2-aminoindan (MEAI) for depression treatment, according to a company statement.

The Vancouver-based clinical-stage biotech company describes MEAI as a non-hallucinogenic molecule designed as an alternative to traditional antidepressants and psychedelic-based therapies. The filing adds to Clearmind's intellectual property portfolio, which includes 19 patent families and 31 granted patents.

Japan has approximately 3 million diagnosed cases of major depressive disorder, the company stated. The global anxiety and depression treatment market is estimated at $16-22.65 billion in 2025, with projections reaching $19-30 billion by 2030-2031.

Clearmind is developing MEAI-based treatments for multiple conditions including alcohol use disorder, metabolic disorders, and various mental health conditions. The company focuses on developing neuroplastogen-derived therapeutics for underserved health problems.

The company trades on Nasdaq under the symbol CMND.